Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NOTA-RM26 PET/CT in Breast Tumor
NCT03347864Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-NOTA-RM26 in breast neoplasm, sponsored by Peking Union Medical College Hospital. Primary endpoint: Standardized uptake value at 1 year. Status: unknown.
02
Drugs
68Ga-NOTA-RM26
03
Conditions
breast neoplasm
Beyond the preview
Go deeper on NCT03347864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03347864.